70 related articles for article (PubMed ID: 11779138)
1. Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta.
Gardner B; Zu LX; Sharma S; Liu Q; Makriyannis A; Tashkin DP; Dubinett SM
Biochem Biophys Res Commun; 2002 Jan; 290(1):91-6. PubMed ID: 11779138
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid receptor-mediated regulation of intracellular calcium by delta(9)-tetrahydrocannabinol in resting T cells.
Rao GK; Zhang W; Kaminski NE
J Leukoc Biol; 2004 May; 75(5):884-92. PubMed ID: 14966196
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid receptors and T helper cells.
Klein TW; Newton C; Larsen K; Chou J; Perkins I; Lu L; Nong L; Friedman H
J Neuroimmunol; 2004 Feb; 147(1-2):91-4. PubMed ID: 14741435
[TBL] [Abstract][Full Text] [Related]
4. Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation.
Bouaboula M; Desnoyer N; Carayon P; Combes T; Casellas P
Mol Pharmacol; 1999 Mar; 55(3):473-80. PubMed ID: 10051530
[TBL] [Abstract][Full Text] [Related]
5. Metabolic stimulation of mouse spleen lymphocytes by low doses of delta9-tetrahydrocannabinol.
Sánchez C; Velasco G; Guzmán M
Life Sci; 1997; 60(19):1709-17. PubMed ID: 9129126
[TBL] [Abstract][Full Text] [Related]
6. Suppression of lymphocyte adenosine 3':5'-cyclic monophosphate (cAMP) by delta-9-tetrahydrocannabinol.
Diaz S; Specter S; Coffey RG
Int J Immunopharmacol; 1993 May; 15(4):523-32. PubMed ID: 8396073
[TBL] [Abstract][Full Text] [Related]
7. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway.
Zhu LX; Sharma S; Stolina M; Gardner B; Roth MD; Tashkin DP; Dubinett SM
J Immunol; 2000 Jul; 165(1):373-80. PubMed ID: 10861074
[TBL] [Abstract][Full Text] [Related]
8. (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase.
Bayewitch M; Rhee MH; Avidor-Reiss T; Breuer A; Mechoulam R; Vogel Z
J Biol Chem; 1996 Apr; 271(17):9902-5. PubMed ID: 8626625
[TBL] [Abstract][Full Text] [Related]
9. Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells.
Gkoumassi E; Dekkers BG; Dröge MJ; Elzinga CR; Schmidt M; Meurs H; Zaagsma J; Nelemans SA
Br J Pharmacol; 2007 Aug; 151(7):1041-8. PubMed ID: 17558435
[TBL] [Abstract][Full Text] [Related]
10. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
Rinaldi-Carmona M; Barth F; Millan J; Derocq JM; Casellas P; Congy C; Oustric D; Sarran M; Bouaboula M; Calandra B; Portier M; Shire D; Brelière JC; Le Fur GL
J Pharmacol Exp Ther; 1998 Feb; 284(2):644-50. PubMed ID: 9454810
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.
Schatz AR; Lee M; Condie RB; Pulaski JT; Kaminski NE
Toxicol Appl Pharmacol; 1997 Feb; 142(2):278-87. PubMed ID: 9070350
[TBL] [Abstract][Full Text] [Related]
12. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
Haller VL; Cichewicz DL; Welch SP
Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265
[TBL] [Abstract][Full Text] [Related]
13. The THC-induced suppression of Th1 polarization in response to Legionella pneumophila infection is not mediated by increases in corticosterone and PGE2.
Newton CA; Lu T; Nazian SJ; Perkins I; Friedman H; Klein TW
J Leukoc Biol; 2004 Oct; 76(4):854-61. PubMed ID: 15258190
[TBL] [Abstract][Full Text] [Related]
14. Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo.
McKallip RJ; Lombard C; Martin BR; Nagarkatti M; Nagarkatti PS
J Pharmacol Exp Ther; 2002 Aug; 302(2):451-65. PubMed ID: 12130702
[TBL] [Abstract][Full Text] [Related]
15. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.
Golech SA; McCarron RM; Chen Y; Bembry J; Lenz F; Mechoulam R; Shohami E; Spatz M
Brain Res Mol Brain Res; 2004 Dec; 132(1):87-92. PubMed ID: 15548432
[TBL] [Abstract][Full Text] [Related]
16. Effect of delta9-tetrahydrocannabinol on phosphorylated CREB in rat cerebellum: an immunohistochemical study.
Casu MA; Pisu C; Sanna A; Tambaro S; Spada GP; Mongeau R; Pani L
Brain Res; 2005 Jun; 1048(1-2):41-7. PubMed ID: 15913574
[TBL] [Abstract][Full Text] [Related]
17. delta(9)-Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells. Involvement of CB1 cannabinoid receptor and Raf-1.
Velasco L; Ruiz L; Sánchez MG; Díaz-Laviada I
Eur J Biochem; 2001 Feb; 268(3):531-5. PubMed ID: 11168391
[TBL] [Abstract][Full Text] [Related]
18. Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors.
Eisenstein TK; Meissler JJ; Wilson Q; Gaughan JP; Adler MW
J Neuroimmunol; 2007 Sep; 189(1-2):17-22. PubMed ID: 17640739
[TBL] [Abstract][Full Text] [Related]
19. SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist.
Portier M; Rinaldi-Carmona M; Pecceu F; Combes T; Poinot-Chazel C; Calandra B; Barth F; le Fur G; Casellas P
J Pharmacol Exp Ther; 1999 Feb; 288(2):582-9. PubMed ID: 9918562
[TBL] [Abstract][Full Text] [Related]
20. Role of cannabinoid receptors in inhibiting macrophage costimulatory activity.
Chuchawankul S; Shima M; Buckley NE; Hartmann CB; McCoy KL
Int Immunopharmacol; 2004 Feb; 4(2):265-78. PubMed ID: 14996418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
